About Inventiva Sa
Inventiva (EPA:IVA), (NASDAQ:IVA) is a biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical need, particularly in the realms of fibrosis, lysosomal storage disorders, and oncology. Its pipeline is led by lanifibranor, which is in Phase IIb development for the treatment of nonalcoholic steatohepatitis (NASH), a serious liver disease. Inventiva is also advancing a second candidate, odiparcil, aimed at treating patients with mucopolysaccharidosis, a group of lysosomal storage disorders. With each project, Inventiva aims to leverage its expertise in nuclear receptor, transcription factor, and epigenetics to discover and develop novel therapeutics. The company is also listed on the Euronext Paris under the ticker (EPA:IVA), indicating its commitment to expanding its reach and enhancing shareholder value through multiple market presences.
Snapshot
Operations
Products and/or services of Inventiva Sa
- Lanifibranor, a treatment targeting non-alcoholic steatohepatitis (NASH) and other fibrotic diseases.
- Research focusing on the development of drugs leveraging the YAP-TEAD transcriptional complex for fibrotic conditions.
- Partnerships for innovative therapies in fibrosis and rare diseases.
- Odiparcil, a therapy aimed at treating mucopolysaccharidoses.
- A range of preclinical candidates addressing various fibrotic diseases.
- Technology platforms for drug discovery, including YAP-TEAD inhibitors.
Inventiva Sa executive team
- Dr. Pierre Broqua Ph.D.Co-Founder
- Dr. Martine Zimmermann Pharm.D.Executive VP of Regulatory Affairs & Quality Assurance
- Mr. Andrew ObenshainCEO & Director
- Mr. Jean VolatierDeputy GM & CFO
- Mr. Eric Duranson L.L.M.General Counsel
- Ms. Nathalie HarroyHead of Human Resources
- Ms. Pascaline Clerc Ph.D.Executive Vice President of External and Corporate Affairs
- Mr. Jason A. Campagna M.D., Ph.D.President of Research and Development & Chief Medical Officer
- Ms. Nazira Amra M.D.Chief Commercial Strategy Officer